Alerus Financial NA Has $328,000 Holdings in Gilead Sciences, Inc. (GILD)
Alerus Financial NA continued to hold its position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,640 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Alerus Financial NA’s holdings in Gilead Sciences were worth $328,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares in the last quarter. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares in the last quarter. American Beacon Advisors Inc. bought a new position in Gilead Sciences during the first quarter worth $143,000. Washington Trust Bank boosted its stake in Gilead Sciences by 24.8% during the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock worth $196,000 after acquiring an additional 550 shares in the last quarter. Finally, Adalta Capital Management LLC bought a new position in Gilead Sciences during the first quarter worth $204,000. 74.38% of the stock is currently owned by institutional investors.
Several research analysts recently issued reports on the stock. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, August 31st. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price on the stock. in a research note on Monday, August 28th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research note on Wednesday, September 6th. Finally, Oppenheimer Holdings, Inc. assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $85.68.
In other news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $83.11, for a total transaction of $6,094,705.63. Following the completion of the transaction, the insider now owns 2,996,766 shares of the company’s stock, valued at $249,061,222.26. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,269,486 in the last quarter. Company insiders own 1.30% of the company’s stock.
Gilead Sciences, Inc. (GILD) opened at $73.21 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.74 and a debt-to-equity ratio of 1.18. The firm has a market cap of $94,600.66, a PE ratio of 7.56, a price-to-earnings-growth ratio of -1.21 and a beta of 1.13. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter last year, the business earned $2.75 earnings per share. sell-side analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences’s dividend payout ratio is presently 23.69%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.